CA2373221A1 - Anticorps humains diriges contre le staphylococcus aureus - Google Patents

Anticorps humains diriges contre le staphylococcus aureus Download PDF

Info

Publication number
CA2373221A1
CA2373221A1 CA002373221A CA2373221A CA2373221A1 CA 2373221 A1 CA2373221 A1 CA 2373221A1 CA 002373221 A CA002373221 A CA 002373221A CA 2373221 A CA2373221 A CA 2373221A CA 2373221 A1 CA2373221 A1 CA 2373221A1
Authority
CA
Canada
Prior art keywords
aureus
human
antigen
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373221A
Other languages
English (en)
Inventor
Yashwant M. Deo
Tibor Keler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373221A1 publication Critical patent/CA2373221A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps monoclonaux humains isolés et des portions de ceux-ci, de liaison à des antigènes, se liant spécifiquement à une ou plusieurs souches de <i>S. aureus</i>, y compris des souches <i>S. aureus</i> résistant à la méthicilline. Les anticorps humains peuvent être produits dans un animal transgénique non humain, par exemple, une souris transgénique, capable de produire de multiples isotypes d'anticorps monoclonaux humains par recombinaison V-D-J et commutation isotype. L'invention concerne également des compositions pharmaceutiques comprenant les anticorps humains, des animaux transgéniques non humains et des hybridomes produisant les anticorps humains. Enfin, l'invention concerne des procédés thérapeutiques et de diagnostic pour l'utilisation des anticorps humains.
CA002373221A 1999-05-03 2000-05-03 Anticorps humains diriges contre le staphylococcus aureus Abandoned CA2373221A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13221299P 1999-05-03 1999-05-03
US60/132,212 1999-05-03
PCT/US2000/012116 WO2000071585A1 (fr) 1999-05-03 2000-05-03 Anticorps humains diriges contre le staphylococcus aureus

Publications (1)

Publication Number Publication Date
CA2373221A1 true CA2373221A1 (fr) 2000-11-30

Family

ID=22452989

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373221A Abandoned CA2373221A1 (fr) 1999-05-03 2000-05-03 Anticorps humains diriges contre le staphylococcus aureus

Country Status (5)

Country Link
EP (1) EP1173485A1 (fr)
JP (1) JP2003503015A (fr)
AU (1) AU5867100A (fr)
CA (1) CA2373221A1 (fr)
WO (1) WO2000071585A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2339344A1 (fr) 2001-06-15 2011-06-29 Inhibitex, Inc. Anticorps monoclonaux et polyclonaux à réaction croisée qui reconnaissent des protéines de surface de staphylocoques à coagulase négative et de staphylocoques dores
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
WO2004034988A2 (fr) 2002-10-16 2004-04-29 Amgen Inc. Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
BRPI0408167B1 (pt) * 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
CN103351435B (zh) * 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
US8735554B2 (en) 2008-05-07 2014-05-27 Innovative Biosensors, Inc. Reagents, methods, and systems for detecting methicillin-resistant Staphylococcus
WO2011005341A2 (fr) 2009-04-03 2011-01-13 University Of Chicago Compositions et méthodes associées aux variants de la protéine a (spa)
MX2012000044A (es) 2009-06-22 2012-01-30 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
CU24180B1 (es) * 2009-08-10 2016-04-25 Fundação Oswaldo Cruz Anticuerpo monoclonal aislado para proteina pbp5
BRPI0914508B1 (pt) * 2009-08-10 2019-04-16 Fundação Oswaldo Cruz ANTICORPOS MONOCLONAIS PARA A PROTEÍNA PBP2a, E, COMPOSIÇÃO FARMACÊUTICA
WO2011017791A1 (fr) * 2009-08-10 2011-02-17 Fundação Oswaldo Cruz ANTICORPS MONOCLONAUX POUR LA PROTÉINE PBP2a ET SÉQUENCES HOMOLOGUES POUR LE TRAITEMENT D'INFECTIONS ET L'IMMUNODIAGNOSTIC DANS DES BACTÉRIES DU PHYLUM FIRMICUTES
ES2773920T3 (es) * 2009-08-10 2020-07-15 Fundacao Oswaldo Cruz Anticuerpos monoclonales contra la proteína PBP2a y secuencias homólogas para el tratamiento de infecciones e inmunodiagnóstico de bacterias del filo Firmicutes
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
CN103890173B (zh) 2011-08-19 2016-02-03 鸵鸟制药株式会社 抗体和含有抗体的组合物
JP5813880B2 (ja) * 2011-09-19 2015-11-17 カイマブ・リミテッド ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP3004161B1 (fr) 2013-05-31 2019-10-02 Genentech, Inc. Anticorps anti-acides téichoïques de paroi et leurs conjugués
MA38686A1 (fr) 2013-05-31 2017-10-31 Genentech Inc Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
EP3226911A1 (fr) 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Conjugués d'anticorps anti staphylocoque doré et de rifamycine et utilisations de ceux-ci
EP3226908A1 (fr) * 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Conjugués de rifamycine et d'anticorps anti-staphylococcus aureus et leurs utilisations
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
CN111671910B (zh) * 2020-06-28 2022-04-26 兴盟生物医药(苏州)有限公司 一种抗葡萄球菌感染的联合抗体制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2625321B1 (fr) * 1987-12-24 1992-10-02 Pasteur Institut Reactif pour le diagnostic de staphylococcus aureus par agglutination
WO1992005793A1 (fr) * 1990-10-05 1992-04-16 Medarex, Inc. Immunostimulation ciblee induite par des reactifs bispecifiques
PT635132E (pt) * 1992-03-19 2001-03-30 Henry M Jackson Found Advanc M Anticorpos opsonicos amplamente reactivos que reagem com antigenios de estafilococos comuns
GB9415900D0 (en) * 1994-08-05 1994-09-28 Smithkline Beecham Plc Novel compounds and treatment
FR2746398B1 (fr) * 1996-03-21 1998-04-30 Bio Merieux Anticorps specifique de staphylococcus aureaus, et utilisations

Also Published As

Publication number Publication date
EP1173485A1 (fr) 2002-01-23
WO2000071585A1 (fr) 2000-11-30
JP2003503015A (ja) 2003-01-28
AU5867100A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
CA2373221A1 (fr) Anticorps humains diriges contre le staphylococcus aureus
AU2002240338C1 (en) Human monoclonal antibodies to FC alpha receptor (CD89)
JP5007409B2 (ja) 樹状細胞に対するヒトモノクローナル抗体
EP1210372B1 (fr) Anticorps monoclonaux humains diriges contre her2/neu
JP4799821B2 (ja) 樹状細胞に対するヒトモノクローナル抗体
CA2450285C (fr) Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr)
AU2002240338A1 (en) Human monoclonal antibodies to FC alpha receptor (CD89)
AU2001261383A1 (en) Human monoclonal antibodies to dendritic cells
AU2002345673A1 (en) Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2004201429A1 (en) Human antibodies to staphylococcus aureus
AU2005200250B2 (en) Human monoclonal antibodies to dendritic cells
AU2006201671A1 (en) Human monoclonal antibodies to HER2/neu
ZA200209056B (en) Human monoclonal antibodies to dendritic cells.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead